Financials

	2025 *	2026 *
Net sales	296M 250M 228M 217M 403M 26.83B 419M 2.65B 1.05B 12.96B 1.11B 1.09B 45.29B	411M 346M 316M 301M 559M 37.19B 581M 3.67B 1.46B 17.96B 1.54B 1.51B 62.77B
Net income	3.49M 2.94M 2.69M 2.56M 4.76M 316M 4.94M 31.23M 12.4M 153M 13.1M 12.83M 534M	14.2M 11.96M 10.91M 10.42M 19.34M 1.29B 20.09M 127M 50.38M 621M 53.24M 52.15M 2.17B
Net Debt	-445M -375M -342M -327M -606M -40.3B -630M -3.98B -1.58B -19.46B -1.67B -1.63B -68.03B	-478M -403M -367M -351M -651M -43.29B -676M -4.27B -1.7B -20.91B -1.79B -1.76B -73.07B

* Estimated data More financial data

Company Profile

Employees

620

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	88.61 $	-1.20%	146,486
12/02/26	89.69 $	+4.61%	223,706
11/02/26	85.74 $	-6.74%	200,691
10/02/26	91.94 $	-0.51%	216,316
09/02/26	92.41 $	+1.99%	182,711

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

88.61USD

Average target price

135.29USD

Spread / Average Target

+52.68%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
88.61 ^USD	-1.20%		-2.21%	+8.27%

02-10	BillionToOne, Inc. Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®	CI
02-09	BillionToOne, Inc. Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs	CI

Capitalization	4.06B 3.42B 3.12B 2.98B 5.52B 367B 5.74B 36.25B 14.39B 177B 15.21B 14.9B 620B	P/E ratio 2025 *	826x	P/E ratio 2026 *	375x
Enterprise value	3.61B 3.04B 2.77B 2.65B 4.92B 327B 5.11B 32.27B 12.81B 158B 13.54B 13.26B 552B	EV / Sales 2025 *	12.2x	EV / Sales 2026 *	8.71x
Free-Float	-	Yield 2025 *	-	Yield 2026 *	-

02-10	BillionToOne, Inc. Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®	CI
02-09	BillionToOne, Inc. Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs	CI
01-29	Nasdaq profit beats estimates; CEO touts IPO pipeline	RE
01-15	BillionToOne to Integrate Testing Portfolio With Epic's Diagnostics Suite	MT
01-15	BillionToOne, Inc. Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare	CI
01-15	Billiontoone announces collaboration with Epic to expand prenatal and oncology testing across healthcare	RE
01-12	BillionToOne Reaffirms 2025 Revenue Guidance, Issues 2026 Guidance	MT
01-12	(BLLN) BillionToOne Expects 2025 Revenue Range $293M - $299M, vs. FactSet Est of $296.2M	MT
01-12	(BLLN) BillionToOne Expects 2026 Total Revenue Range $415M to $430M, vs. FactSet Est of $402.3M	MT
01-12	Billiontoone provides guidance for 2026	RE
01-12	Billiontoone, Inc. Provides Earnings Guidance for 2026	CI
01-06	BillionToOne, Inc. Announces Selection of Northstar Select as New Liquid Biopsy Test for LC-SCRUM-TRY Clinical Study at National Cancer Center Hospital East	CI
01-06	Billiontoone announces selection of Northstar Select® as the new liquid biopsy test	RE

01-06	Guggenheim Initiates BillionToOne at Buy With $120 Price Target	MT
12-09	(BLLN) BillionToOne Expects Full Year 2025 Revenue Range $293M - $299M, vs. FactSet Est of $288.6M	MT
12-01	BillionToOne Shares Fall After Jefferies Initiates Coverage at Hold	MT
12-01	Jefferies Initiates BillionToOne at Hold With $117 Price Target	MT
12-01	Stifel Initiates BillionToOne at Buy With $145 Price Target	MT

BillionToOne, Inc. Share Price

Equities

BLLN

US0901681058

Biotechnology & Medical Research

Valuation: BillionToOne, Inc.

Chart: BillionToOne, Inc.

Latest news: BillionToOne, Inc.

Last Transcript: BillionToOne, Inc.

Analysts' recommendations: BillionToOne, Inc.

Press Releases: BillionToOne, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BillionToOne, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-16	BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare	AQ
01-12	BillionToOne Provides Guidance for 2026	GL
12-23	BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference	GL
12-09	BillionToOne Reports Third Quarter 2025 Results	GL
12-02	BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025	GL

1 day	-1.20%
1 week	-2.21%
Current month	+7.39%
1 month	-8.51%
3 months	-1.05%
Current year	+8.27%

1 week	84.49	98.26
1 month	80	98.26
Current year	80	101.98
1 year	80	138.7
3 years	80	138.7
5 years	80	138.7
10 years	80	138.7

Manager	Title	Age	Since
David Tsao PSD	President	37	31/12/2015
Atay Oguzhan CEO	Chief Executive Officer	38	31/12/2015
Ross Taylor DFI	Director of Finance/CFO	62	31/12/2023

Director	Title	Age	Since
Atay Oguzhan CHM	Chairman	38	31/12/2015
David Tsao BRD	Director/Board Member	37	31/12/2015
Kittu Kolluri BRD	Director/Board Member	62	28/02/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BILLIONTOONE, INC.	-1.20%	-2.21%	-	-	4.06B
LONZA GROUP AG	+4.62%	+0.73%	-12.88%	-4.40%	47.61B
BEONE MEDICINES AG	-0.10%	-2.22%	+53.47%	+41.20%	38.3B
CELLTRION, INC.	-0.21%	+8.18%	+39.13%	+61.33%	36.11B
IQVIA HOLDINGS INC.	-1.13%	-10.96%	-14.85%	-28.08%	28.31B
REVOLUTION MEDICINES, INC.	-1.05%	-1.21%	+133.08%	+277.09%	18.62B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+7.58%	+14.65%	+33,042.25%	+4,133.79%	15.44B
EUROFINS SCIENTIFIC SE	+2.25%	-3.74%	+29.62%	-3.02%	13.72B
ASCENDIS PHARMA A/S	-0.82%	-2.62%	+51.81%	+89.94%	13.28B
IONIS PHARMACEUTICALS, INC.	-1.44%	-6.82%	+165.57%	+103.18%	13.06B
Average	+0.85%	-1.09%	+3,720.80%	+519.00%	22.85B
Weighted average by Cap.	+1.18%	-0.94%	+2,309.25%	+330.90%